The European deadline for data collection and reporting of pharma to HCP/HCO (healthcare organisation) spend is drawing ever closer – from January 2016, healthcare companies will be duty bound to publicly disclose all transfers of value (TOV) made to HCPs and HCOs in accordance with the 2014 EFPIA Disclosure code.
While opinion may be divided as to the merits of this code, or even the end objective, it cannot be argued that its introduction has led pharma companies to re-evaluate their marketing strategies, events policies, systems and processes.
In doing so, the EFPIA code, much the same as its US counterpart, the Open Payments Act, has created a ‘micro-industry’ within pharma, designed specifically to accommodate the code to ensure its compliance and greater transparency across the industry.
10 Ways … to meet event disclosure rules focuses on the disclosure of meetings and eventsspend, and Ashfield Meetings & Events highlight 10 steps to take to achieve full TOV disclosure.
